U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshots: RYLAZE
  1. Drug Approvals and Databases

Drug Trials Snapshots: RYLAZE

HOW TO USE THIS SNAPSHOT
The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

LIMITATIONS OF THIS SNAPSHOT
Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable). Refer to the RYLAZE Prescribing Information for all of the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn)
(Rye layz’)
Jazz Pharmaceuticals Ireland Limited
Original Approval date: June 30, 2021


DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

RYLAZE is used with other chemotherapy drugs for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and children 1 month or older who have developed an allergic reaction (hypersensitivity) to E. coli-derived asparaginase.

ALL is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of leukemia cells (lymphoblasts, a type of white blood cell) in the bloodstream.

LBL is a rare, rapidly progressing cancer of immature lymphocytes (lymphoblasts), most often seen in teenagers and young adults.

How is this drug used?

RYLAZE is given as an injection into the muscle. The number of injections and duration of treatment are determined by the healthcare provider.

Who participated in the clinical trials?

The FDA approval of RYLAZE was based on evidence from one ongoing clinical trial (NCT04145531) in 102 children and adult patients with a type of cancer called ALL/LBL. These patients had developed allergy to another type of asparaginase.

The trial was conducted in 67 sites across the United States and Canada.

Data for the evaluation of benefit (efficacy) is from 101 patients treated with RYLAZE in this trial. Demographics of the efficacy population is presented below in Figure 1, Figure 3, Figure 5, and Figure 7.

Data for the evaluation of side effects of RYLAZE (safety) is from a subset of 33 patients. Demographics of the safety population that provided data for side effects of RYLAZE is presented below in Figure 2, Figure 4, Figure 6, and Figure 8.

The number of patients representing efficacy findings may differ from the number of patients representing safety findings due to different pools of study participants analyzed for efficacy and safety.

What are the benefits of this drug?

RYLAZE is a type of medication called asparaginase. Asparaginase is an important medication used in patients with ALL and LBL that breaks down the amino acid asparagine. Leukemic cells are unable to make their own asparagine and die when asparagine is removed by RYLAZE.

RYLAZE is a different type of asparaginase that can be used in patients that develop allergy to another asparaginase. This is how this medication helps leukemia patients.

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

  • Sex: RYLAZE worked similarly in males and females.
  • Race: RYLAZE worked similarly across different races and ethnicities.
  • Age: RYLAZE worked similarly in children and adult patients.

What are the possible side effects?

RYLAZE may cause serious allergic reactions, inflammation of pancreas, blood clots, bleeding, or liver damage.

The most common side effects of RYLAZE when given in combination with chemotherapy for the treatment of ALL and LBL are abnormal liver tests, nausea, muscle and bone pain, and fatigue.

Were there any differences in side effects among sex, race and age?

  • Sex: The differences in side effects among sex could not be determined.
  • Race: The number of patients of races other than White was small; therefore, differences in side effects among races could not be determined.
  • Age: The number of adult patients was small; therefore differences in side effects among races could not be determined.

Demographics Snapshot

Figure 1 summarizes how many men and women were enrolled in the clinical trial used to evaluate the efficacy of RYLAZE.

Figure 1. Baseline Demographics by Sex (Evaluation of Efficacy)

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 58 (57%) Male patients, and 43 (43%) female patients participated in the clinical trial to evaluate efficacy.

Source: Adapted from FDA Review

Figure 2 summarizes how many patients by sex were used to evaluate the side effects of RYLAZE.

Figure 2. Baseline Demographics by Sex (Evaluation of Safety)

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 17 (52%) Male patients, and 16 (48%) female patients participated in the clinical trial to evaluate safety.

Source: Adapted from FDA Review

Figure 3 summarizes how many patients by race enrolled in the clinical trial used to evaluate the efficacy of RYLAZE.

Figure 3. Baseline Demographics by Race (Evaluation of Efficacy)

Pie chart summarizing how many White, Black, Asian, and other patients were in the clinical trial.  In total, 73 (72%) white patients, 12(12%) black patients, 5(5%) Asian patients, and 11 (11%) Other patients participated in the clinical trial to evaluate efficacy.

*Other includes American Indian or Alaska Native, Multiple, or Not Reported

Source: Adapted from FDA Review

Figure 4 summarizes how many patients by race were used to evaluate the side effects of RYLAZE.

Figure 4. Baseline Demographics by Race (Evaluation of Safety)

Pie chart summarizing how many White, Black, Asian, and other patients were in the clinical trial.  In total, 24 (73%) white patients, 3(9%) black patients, 1(3%) Asian patients, and 5 (15%) Other patients participated in the clinical trial to evaluate safety.

*Other includes Multiple or Not Reported

Figure 5 summarizes how many patients by age enrolled in the clinical trial used to evaluate the efficacy of RYLAZE.

Figure 5. Baseline Demographics by Age (Evaluation of Efficacy)

Pie chart summarizing how many patients by age were in the clinical trial. In total, 29(29%) patients were between the age of 1 and 5, 34(33%) patients were between the age of 6 and 11 years of age, 26 (26%) patients were between the age of 12 and 17, and 12(12%) we 18 years of age or older that participated in the clinical trial to evaluate efficacy.

Source: Adapted from FDA Review

Figure 6 summarizes how many patients by age were used to evaluate the side effects of RYLAZE.

Figure 6. Baseline Demographics by Age (Evaluation of Safety)

Pie chart summarizing how many patients by age were in the clinical trial. In total, 9(28%) patients were between the age of 1 and 5, 9(27%) patients were between the age of 6 and 11 years of age, 7 (21%) patients were between the age of 12 and 17, and 8(24%) we 18 years of age or older that participated in the clinical trial to evaluate safety.

Source: Adapted from FDA Review

Figure 7 summarizes how many patients by ethnicity enrolled in the clinical trial used to evaluate the efficacy of RYLAZE.

Figure 7. Baseline Demographics by Ethnicity (Evaluation of Efficacy)

Pie chart summarizing how many hispanics and non-hispanics were in the clinical trial.  In total, 34(23%) hispanic patients,  and 63(62%) non-hispanic patients, and 4(4%) declined to state,  participated in the clinical trial to evaluate efficacy.

Source: Adapted from FDA Review

Figure 8 Summarizes how many patients by ethnicity were used to evaluate the side effects of RYLAZE.

Figure 8. Baseline Demographics by Ethnicity (Evaluation of Safety)

Pie chart summarizing how many hispanics and non-hispanics were in the clinical trial to evaluate safety.  In total, 13(39%) hispanic patients,  and 18(55%) non-hispanic patients, and 2(6%) declined to state,  participated in the clinical trial to evaluate safety.

Source: Adapted from FDA Review

How were the trials designed?

The benefits and side effects of RYLAZE were evaluated from one ongoing clinical trial (NCT04145531).

Patients with ALL or LBL received RYLAZE after they developed allergy to an E.coli based long acting asparaginase.

The trial enrolled patients of all ages. All patients received RYLAZE as part of a combination of drugs used for treatment of ALL/LBL.

Patients received 6 doses of RYLAZE to make up for each dose of a prior long acting asparaginase therapy as prescribed by the doctor. Doses were given on a Monday, Wednesday, and Friday schedule for two consecutive weeks.

The benefit of RYLAZE was evaluated by measuring serum asparaginase levels at predefined time points after RYLAZE treatment.

GLOSSARY

CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

PRESCRIBING INFORMATION

Back to Drug Trials Snapshots

Back to Top